Sanofi Wins FDA Approval for First Neurological Gaucher Disease Treatment
Sanofi has received approval from the US Food and Drug Administration (FDA) for Infilbray (venglustat), making it the first medicine approved to treat the neurological symptoms of Type 3 Gaucher disease (GD3).
Announced on November 18, 2026, the approval covers adults and pediatric patients weighing at least 15 kg. Infilbray is a once-daily oral medicine designed to cross the blood-brain barrier and address neurological complications associated with this rare genetic disorder.
Type 3 Gaucher disease is an inherited condition in which a lack of a specific enzyme causes harmful fatty substances to build up in different organs and tissues. The disease can affect the liver, spleen, bones and central nervous system. Patients may experience problems with movement, balance, coordination and cognitive function.
Until now, available treatments have mainly focused on managing the physical symptoms of the disease. However, addressing neurological complications has remained a major challenge because many existing treatments cannot effectively reach the brain.
Infilbray works by inhibiting an enzyme called glucosylceramide synthase. This enzyme plays a role in producing glucosylceramide, a fatty substance that accumulates in people with Gaucher disease. By reducing its production, venglustat aims to limit the buildup of these substances in the body, including the central nervous system.
The FDA approval was supported by positive results from the Phase 3 LEAP2MONO study, which evaluated the medicine in patients with Type 3 Gaucher disease who had already achieved stable control of their systemic symptoms with enzyme replacement therapy.
The study compared Infilbray with imiglucerase, an established enzyme replacement treatment. Results showed that patients receiving Infilbray achieved statistically significant improvements in neurological symptoms compared with those receiving imiglucerase.
The assessment included measures of ataxia, which affects balance and coordination, and cognitive function. The combined analysis of these neurological measures demonstrated statistically significant superiority for Infilbray at Week 52, with a p-value of 0.0137.
The study included adults and pediatric patients aged 12 years and older. Participants were assessed using the modified Scale for the Assessment and Rating of Ataxia (SARA) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
Infilbray previously received Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations from the FDA, supporting its development for this rare condition.
Manuela Buxo, Executive Vice President and Global Head of Specialty Care at Sanofi, said the approval represents an important addition to the company’s rare disease portfolio and reflects its commitment to developing treatments for patients with significant unmet medical needs.
The company is also pursuing regulatory reviews for Infilbray in Europe, Japan and other markets, with additional submissions planned during 2026 and 2027.
The approval marks an important development in rare disease treatment, as Infilbray offers a new option for patients with Type 3 Gaucher disease whose neurological symptoms have remained difficult to manage with existing therapies.
